Strength Training Induced Alterations in Markers of Immune Function

October 10, 2011 updated by: Laura Stewart, Louisiana State University Health Sciences Center in New Orleans

Exercise has been used to help prevent or slow the progression of inflammation-related disease; however, the mechanism by which this activity may lower concentrations of inflammatory markers remains unclear. The melanocortin receptors 1,3 and 5 (MC1R, MC3R and MC5R) have been shown to function in an anti-inflammatory manner and have the potential to mediate the positive immune adaptations associated with regular physical activity.

Preliminary data suggest that MC3R gene expression increases in whole blood after chronic exercise training. The primary aim of the current study is to explore whether this change in gene expression translates into alterations in MC1R, MC3R, or MC5R monocyte surface expression. The secondary aim is to examine the relationship between surface expression of these receptors and circulating inflammatory profiles.

The investigators will recruit 42 untrained, healthy males and females aged 18-35 yrs. Half of the group will be placed on an exercise program for 15 weeks. The other half will serve as untrained control subjects. In addition to basic anthropometric measures, the investigators will measure concentrations of inflammatory and anti-inflammatory cytokines (ELISA) and cell surface expression of MC1R, MC3R, and MC5R on monocytes (flow cytometry).

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

Abstract:

Chronic exercise reduces inflammation, but the mechanisms involved are unclear. Recent studies have shown that stimulation of melanocortin 1 and 3 receptors (MC1R and MC3R) on immune cells increases anti-inflammatory cytokine production. PURPOSE: To examine the influence of 12 weeks of resistance training (RT) on body composition, monocyte cell-surface expression of MC1R and MC3R and circulating markers of inflammation. METHODS: Healthy, active males and females (age 20-27 yr) were recruited into a RT group (RE; n = 23) and an active control group (AC; n = 19). RE completed 12 weeks of progressive, periodized RT 3d/wk while AC maintained normal activity habits. Measures of body composition (DXA) were taken and blood was collected prior to (PRE) and following the intervention period (POST). Blood samples were analyzed for monocyte cell-surface expression MC1R, MC3R, MC5R and C-reactive protein (CRP) and the plasma cytokines interleukin 6 (IL-6) and interleukin 10 (IL-10) using flow cytometry and ELISAs respectively.

Study Type

Interventional

Enrollment (Actual)

42

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Louisiana
      • Baton Rouge, Louisiana, United States, 70803
        • Louisiana State University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 30 years (Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • All Participants Must be Healthy
  • The Strength Training Group Members Must Be Approved For Participation by a Licensed MD

Exclusion Criteria:

  • Females may not be pregnant
  • Unhealthy participants (those with existing conditions)

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Non-Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Strength Training
The strength training group completed 12 weeks of progressive, periodized resistance training 3d/wk.
Each Member of this group completed 12 weeks of progressive, periodized resistance training for 3d/wk.
No Intervention: Active Control Group
The active control group was instructed to maintain normal activity and eating habits. They participated in all pre and post intervention measures.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Melanocortin 1 Receptor Expression on Monocytes
Time Frame: Before and After 12 Week of Intervention Period
Blood samples were analyzed for monocyte cell-surface expression of the melanocortin 1 receptor using flow cytometry. Pre samples were collected in Jan. 2010 and post samples were collected in May 2010 from all subjects.
Before and After 12 Week of Intervention Period
Plasma CRP
Time Frame: Before and After the 12 Week Intervention Period
Blood samples were analyzed for C-reactive protein using ELISA. Pre samples were collected in Jan. 2010 and post samples were collected in May 2010 from all subjects.
Before and After the 12 Week Intervention Period
Body Composition (Fat Tissue Amount)
Time Frame: Before and After the 12 Week Intervention Period
Body composition was assessed using DXA. Pre measures were completed in Jan. 2010 and post measures were completed in May 2010 for all subjects.
Before and After the 12 Week Intervention Period
Plasma IL-6
Time Frame: Before and After the 12 Week Intervention Period
Blood samples were analyzed for IL-6 using ELISA. Pre samples were collected in Jan. 2010 and post samples were collected in May 2010 from all subjects.
Before and After the 12 Week Intervention Period
Plasma IL-10
Time Frame: Before and After the 12 Week Intervention Period
Blood samples were analyzed for IL-10 using ELISA. Pre samples were collected in Jan. 2010 and post samples were collected in May 2010 from all subjects.
Before and After the 12 Week Intervention Period
Melanocortin 3 Receptor Cell Surface Expression on Monocytes
Time Frame: Before and After the 12 Week Intervention Period
Blood samples were analyzed for monocyte cell-surface expression of the melanocortin 3 receptor using flow cytometry. Pre samples were collected in Jan. 2010 and post samples were collected in May 2010 from all subjects.
Before and After the 12 Week Intervention Period
Melanocortin 5 Receptor Cell Surface Expression on Monocytes
Time Frame: Before and After the 12 Week Intevention Period
Blood samples were analyzed for monocyte cell-surface expression of the melanocortin 5 receptor using flow cytometry. Pre samples were collected in Jan. 2010 and post samples were collected in May 2010 from all subjects.
Before and After the 12 Week Intevention Period

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Laura K Stewart, PhD, Louisiana State University Health Sciences Center in New Orleans

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

January 1, 2010

Primary Completion (Actual)

May 1, 2010

Study Completion (Actual)

May 1, 2010

Study Registration Dates

First Submitted

October 3, 2011

First Submitted That Met QC Criteria

October 10, 2011

First Posted (Estimate)

October 12, 2011

Study Record Updates

Last Update Posted (Estimate)

October 12, 2011

Last Update Submitted That Met QC Criteria

October 10, 2011

Last Verified

October 1, 2011

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • LSU-IRB # 3005

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Inflammation

Clinical Trials on Strength Training

Subscribe